Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibitionSarah E. Sheppard, Håkon Håkonarson, Michael March et al.|JCI Insight|2023Cited by 37
Expanded phenotypic and hematologic abnormalities beyond bone marrow failure in <i>MECOM</i>‐associated syndromesMichell M. Lozano Chinga, Taizo A. Nakano, Joanne I. Hsu et al.|American Journal of Medical Genetics Part A|2023Cited by 18